Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Self-citationSmit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456 · cited 1×
“cgi?l=5244">MDR3 (sometimes called MDR2), a phosphatidylcholine FLIPPASE that is closely related to PGP, normally transports phospholipids into bile, but can transport paclitaxel and vinblastine, albeit inefficiently unless it is mutate”
BackgroundExpression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
Self-citationSchinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264 · cited 1×
“The BBB is formed by the endothelial cells of capillaries, with PGP located on the luminal surface, preventing the penetration of cytotoxins across the endotheliu”
BackgroundMaliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Self-citationCordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062 · cited 1×
“In the placenta, PGP is localized on the apical syncytiotrophoblast surface, where it can protect the fetus from toxic cationic xenobiotic”
BackgroundGros, P., Croop, J., & Housman, D. (1986) · Cell · doi:10.1016/0092-8674(86)90594-5 · Cited by 1,031
Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., et al. (1998) · Nature Genetics · doi:10.1038/3034 · Cited by 995 · cited 1×
“Mutations in BSEP are associated with progressive familial intrahepatic cholestasis type-2, which is characterized by reduced secretion of bile salts and hepatic failur”
BackgroundThe Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver
Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F., & Meier, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.10046 · Cited by 939
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
Chaudhary, P. M., & Roninson, I. B. (1991) · Cell · doi:10.1016/0092-8674(91)90141-k · Cited by 934 · cited 1×
“Previous studies had shown that PGP was expressed and 'active' in haematopoietic stem cell”
ResultMiyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 929
Self-citationThe role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917 · cited 1×
“Studies have shown increased tissue absorption of putative PGP substrates following oral administration when a PGP inhibitor is administered concurrentl”
BackgroundAllikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 916
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882 · cited 1×
“Additionally, PGP actively secretes intravenously administered drugs into the gastrointestinal trac”
BackgroundThe orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene
Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., & Elferink, R. P. J. O. (1996) · Science · doi:10.1126/science.271.5252.1126 · Cited by 822 · cited 1×
“Mutations that disrupt MRP2 function cause bilirubin accumulation and jaundice in rat”
König, J., Nies, A. T., Cui, Y., Leier, I., & Keppler, D. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00169-8 · Cited by 791
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Mutations in the MDR 3 gene cause progressive familial intrahepatic cholestasis
de Vree, J. M. L., Jacquemin, E., Sturm, E., Cresteil, D., Bosma, P. J., Aten, J., Deleuze, J.-F., Desrochers, M., Burdelski, M., Bernard, O., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.282 · Cited by 735
Active outward transport of daunomycin in resistant ehrlich ascites tumor cells
Danø, K. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90191-0 · Cited by 723
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680 · cited 1×
“Studies have shown increased tissue absorption of putative PGP substrates following oral administration when a PGP inhibitor is administered concurrentl”
BackgroundMRP3, an organic anion transporter able to transport anti-cancer drugs
Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M. L., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6914 · Cited by 645
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638 · cited 1×
“MRP family members and the half-transporter ABCG2 are also localized in placent”
BackgroundMüller, M., Meijer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G., & Jansen, P. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.13033 · Cited by 617 · cited 1×
“MRP1 recognizes neutral and anionic hydrophobic natural products, and transports glutathione and other conjugates of these drugs, or, in some cases — such as for vincristine — co-transports unconjugated glutathion”
BackgroundHyafil, F., Pauwels-Vergely, C., Vignaud, P. D., & Grand‐Perret, T. (1993) · PubMed · Cited by 608
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603 · cited 1×
“Impaired drug delivery can result from poor absorption of orally administered drugs, increased drug metabolism or increased excretion, resulting in lower levels of drug in the blood and reduced diffusion of drugs from the blood into the tumour mas”
BackgroundPhosphatidylcholine translocase: A physiological role for the mdr2 gene
Ruetz, S. (1994) · Cell · doi:10.1016/0092-8674(94)90446-4 · Cited by 599
Mutations in ABCC6 cause pseudoxanthoma elasticum
Bergen, A. A. B., Plomp, A. S., Schuurman, E. J., Terry, S., Breuning, M., Dauwerse, H., Swart, J., Kool, M., van Soest, S., Baas, F., et al. (2000) · Nature Genetics · doi:10.1038/76109 · Cited by 593
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
Schuetz, J. D., Connelly, M. C., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A., & Fridland, A. (1999) · Nature Medicine · doi:10.1038/12487 · Cited by 575
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
BindingDB (2013) · PubMed · doi:10.7270/q2q81fck · Cited by 571
Paulusma, C. C., Kool, M., Bosma, P. J., Scheffer, G. L., ter Borg, F., Scheper, R. J., Tytgat, G. N., Borst, P., Baas, F., & Elferink, R. O. (1997) · Hepatology · doi:10.1002/hep.510250635 · Cited by 552 · cited 1×
“gov/htbin-post/Omim/dispmim?237500">Dubin–Johnson syndrome”
Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum
Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., Pasquali-Ronchetti, I., Pope, F. M., Richards, A., Terry, S., et al. (2000) · Nature Genetics · doi:10.1038/76102 · Cited by 540
Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., & Piwnica-Worms, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3900 · Cited by 531
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
Wijnholds, J., Mol, C. A. A. M., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., Beijnen, J. H., Scheper, R. J., Hatse, S., De Clercq, E., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120159197 · Cited by 478
Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR 1
Sorrentino, B. P., Brandt, S. J., Bodine, D., Gottesman, M., Pastan, I., Cline, A., & Nienhuis, A. W. (1992) · Science · doi:10.1126/science.1352414 · Cited by 477
Self-citationLoe, D. W., Deeley, R. G., & Cole, S. P. C. (1998) · PubMed · Cited by 458
Chan, H. S., Thorner, P. S., Haddad, G., & Ling, V (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.4.689 · Cited by 451
The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides
Jedlitschky, G., Burchell, B., & Keppler, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005463200 · Cited by 442
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434
Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A. A. M., Zaman, G. J. R., Mayer, U., Beijnen, J. H., Valk, M. V. D., Krimpenfort, P., & Borst, P. (1997) · Nature Medicine · doi:10.1038/nm1197-1275 · Cited by 432 · cited 1×
“cgi?l=17250"> Mrp1 -null mice have not been found to have alterations in drug pharmacokinetic”
BackgroundHonjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Pérez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M. C., & Bates, S. E. (2001) · PubMed · Cited by 429
Self-citationList, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419 · cited 1×
“In addition, a large prospective randomized study of AML patients reported an increase in relapse-free and overall survival for patients receiving cyclosporin”
BackgroundKool, M., van der Linden, M., de Haas, M., Baas, F., & Borst, P. (1999) · PubMed · Cited by 414
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399 · cited 1×
“Other methodologies, however, have been used to substantiate and refute these findings, and there has been no consensus regarding the effect of PGP on survival in sarcoma”
ResultKartenbeck, J., Leuschner, U., Mayer, R., & Keppler, D. (1996) · Hepatology · doi:10.1002/hep.510230519 · Cited by 398
Transport of Cyclic Nucleotides and Estradiol 17-β-d-Glucuronide by Multidrug Resistance Protein 4
Chen, Z.-S., Lee, K., & Kruh, G. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104833200 · Cited by 396
Ringpfeil, F., Lebwohl, M. G., Christiano, A. M., & Uitto, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100041297 · Cited by 394
Beck, W. T., Grogan, T. M., Willman, C. L., Cordon‐Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., et al. (1996) · PubMed · Cited by 384
Self-citationWang, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031465498 · Cited by 340 · cited 1×
“Mutations in BSEP are associated with progressive familial intrahepatic cholestasis type-2, which is characterized by reduced secretion of bile salts and hepatic failur”
BackgroundLee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Self-citationDantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F., & Starling, J. J. (1996) · PubMed · Cited by 328
Expression of members of the multidrug resistance protein family in human term placenta
St-Pierre, M. V., Serrano, M. A., Macias, R. I. R., Dubs, U., Hoechli, M., Lauper, U., Meier, P. J., & Marin, J. J. G. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1495 · Cited by 325
Modulation of multidrug-resistant multiple myeloma by cyclosporin
Sonneveld, P., Lowenberg, B., Durie, B. G. M., Lokhorst, H. M., Marie, J.-P., Zittoun, R., Solbu, G., Suciu, S., & Nooter, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)92353-h · Cited by 316 · cited 1×
“Similar observations were made in patients with other PGP-expressing malignancie”
ResultCeramide glycosylation potentiates cellular multidrug resistance
LIU, Y., HAN, T., GIULIANO, A. E., & CABOT, M. C. (2001) · The FASEB Journal · doi:10.1096/fj.00-0223com · Cited by 303 · cited 1×
“Alternatively, cells might acquire changes in apoptotic pathways during exposure to chemotherapy, such as alteration of ceramide level”
BackgroundABC transporters in lipid transport
Borst, P., Zelcer, N., & van Helvoort, A. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00053-6 · Cited by 300 · cited 1×
“cgi?l=5244">MDR3 (sometimes called MDR2), a phosphatidylcholine FLIPPASE that is closely related to PGP, normally transports phospholipids into bile, but can transport paclitaxel and vinblastine, albeit inefficiently unless it is mutate”
BackgroundLum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., & Sikic, B. I. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1635 · Cited by 299
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Self-citationMechetner, E. B., Kyshtoobayeva, A. S., Zonis, S., Kim, H. J., Stroup, R., Garcia, R., Parker, R. J., & Fruehauf, J. P. (1998) · PubMed · Cited by 291
Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR
Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., & Sugiyama, Y. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.272.1.g16 · Cited by 290
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., & Dalton, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1652 · Cited by 274
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269 · cited 1×
“Studies have shown increased tissue absorption of putative PGP substrates following oral administration when a PGP inhibitor is administered concurrentl”
BackgroundEvers, R., Zaman, G. J., van Deemter, L., Jansen, H., Calafat, J., Oomen, L. C., Oude Elferink, R. P., Borst, P., & Schinkel, A. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118535 · Cited by 260 · cited 1×
“In contrast to PGP, MRP1 is located in the basolateral membrane of mucosal cells, and therefore transports substrates into the interstitium and the bloodstream, rather than across the apical surface into the intestinal lume”
BackgroundAcromegaly and gastrointestinal cancer
Ron, E., Gridley, G., Hrubec, Z., Page, W., Arora, S., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19911015)68:8<1673::aid-cncr2820680802>3.0.co;2-0 · Cited by 250
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
Ross, D. D., Karp, J. E., Chen, T. T., & Doyle, L. A. (2000) · Blood · doi:10.1182/blood.v96.1.365 · Cited by 250 · cited 1×
“Finally, low expression levels of BCRP/MXR have been observed in AML cell”
BackgroundHuman P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State
Ramachandra, M., Ambudkar, S. V., Chen, D., Hrycyna, C. A., Dey, S., Gottesman, M. M., & Pastan, I. (1998) · Biochemistry · doi:10.1021/bi973045u · Cited by 249 · cited 1×
“Binding of substrate to the transmembrane regions stimulates the ATPase activity of PGP, causing a conformational change that releases substrate to either the outer leaflet of the membrane (from which it can diffuse into the medium) or the extracellular spac”
BackgroundSelf-citationAbolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., BURT, M. E., & Scotto, K. W. (1999) · PubMed · Cited by 231
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Bradshaw, D. M., & Arceci, R. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3674 · Cited by 223
lzquierdo, M. A., Zee, A. G. J. V. D., Vermorken, J. B., Valk, P. V. D., Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1230 · Cited by 220
Sauna, Z. E., & Ambudkar, S. V. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.6.2515 · Cited by 218 · cited 1×
“Hydrolysis at the second ATP site seems to be required to 're-set' the transporter so that it can bind substrate again, completing one catalytic cycl”
BackgroundClinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214 · cited 1×
“Early speculation was replaced by reality as these agents were found to be weak inhibitors that were toxic at high dose”
BackgroundScheffer, G. L., Kool, M., Heijn, M., de Haas, M., Pijnenborg, A. C. L. M., Wijnholds, J., van Helvoort, A., de Jong, M. C., Hooijberg, J. H., Mol, C. A. A. M., et al. (2000) · PubMed · Cited by 210
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R. G., Boersma, T., & Sonneveld, P. (1995) · PubMed · Cited by 210
Xie, R., Hammarlund‐Udenaes, M., De Boer, A. G., & De Lange, E. C. M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702804 · Cited by 203
Bunting, K. D., Galipeau, J., Topham, D., Benaim, E., & Sorrentino, B. P. (1998) · Blood · doi:10.1182/blood.v92.7.2269 · Cited by 191
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., & Sikic, B. I. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.835 · Cited by 189
Legrand, O., Simonin, G., Beauchamp-Nicoud, A., Zittoun, R., & Marie, J.-P. (1999) · Blood · doi:10.1182/blood.v94.3.1046.415k03_1046_1056 · Cited by 179
Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer
Scheffer, G. L., Schroeijers, A. B., Izquierdo, M. A., Wiemer, E. A. C., & Scheper, R. J. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00007 · Cited by 176
Young, L. C., Campling, B. G., Voskoglou-Nomikos, T., Cole, S. P. C., Deeley, R. G., & Gerlach, J. H. (1999) · PubMed · Cited by 168
Del Vecchio, S., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., Thomas, R., Cerra, M., D'Aiuto, G., Tsuruo, T., et al. (1997) · European Journal of Nuclear Medicine · doi:10.1007/bf02439547 · Cited by 163
Clinical Studies with Modulators of Multidrug Resistance
Fisher, G. A., & Sikic, B. I. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30099-6 · Cited by 163
Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., et al. (1999) · Blood · doi:10.1182/blood.v93.3.787 · Cited by 158
Nooter, K., Brutel de la Riviere, G., Look, M., van Wingerden, K., Henzen-Logmans, S., Scheper, R., Flens, M., Klijn, J., Stoter, G., & Foekens, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.414 · Cited by 153
99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
Hendrikse, N. H., Franssen, E. J. F., van der Graaf, W., Meijer, C., Piers, D., Vaalburg, W., & de Vries, E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.57 · Cited by 152
Struk, B., Cai, L., Zäch, S., Ji, W., Chung, J., Lumsden, A., Stumm, M., Huber, M., Schaen, L., Kim, C.-A., et al. (2000) · Journal of molecular medicine · doi:10.1007/s001090000114 · Cited by 146
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 145
The effect of verapamil on the pharmacokinetics of adriamycin
Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J., & Kaye, S. B. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00273394 · Cited by 145 · cited 1×
“Excellent reviews cataloguing completed trials are availabl”
MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver
Belinsky, M. G., & Kruh, G. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690527 · Cited by 143
Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
Moscow, J. A., Huang, H., Carter, C., Hines, K., Zujewski, J., Cusack, G., Chow, C., Venzon, D. J., Sorrentino, B. P., Chiang, Y. L., et al. (1999) · Blood · doi:10.1182/blood.v94.1.52.413k35_52_61 · Cited by 142
Self-citationTaxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein.
Childs, S. J., Yeh, R. L., Hui, D., & Ling, V. W. T. (1998) · PubMed · Cited by 141
Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00111-6 · Cited by 135 · cited 1×
“Excellent reviews cataloguing completed trials are availabl”
Böhme, M., Büchler, M., Müller, M., & Keppler, D. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80403-h · Cited by 132 · cited 1×
“Or, for example, PSC-833 and cyclosporin A inhibit BSEP and reduce the secretion of bile salts, so they might reduce bile flow and slow hepatic excretion of chemotherapeutic agent”
BackgroundP-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
Chan, H. S. L., Haddad, G., DeBoer, G., Ling, V. W. T., & Grogan, T. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1706 · Cited by 132
Dietrich, C. G., de Waart, D. R., Ottenhoff, R., Schoots, I. G., & Elferink, R. P. J. O. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.5.974 · Cited by 131
Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L.-B., & Schuetz, J. D. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26438-5 · Cited by 128
van den Heuvel‐Eibrink, M. M., Sonneveld, P., & Pieters, R. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38094 · Cited by 124
Luker, G. D., Fracasso, P. M., Dobkin, J. B., & Piwnica-Worms, D. (1997) · PubMed · Cited by 120
van der Kolk, D. M., de Vries, E. G. E., Putten, W. J. V., Verdonck, L. F., Ossenkoppele, G. J., Verhoef, G. E. G., & Vellenga, E. (2000) · PubMed · Cited by 118
P-Glycoprotein Shows Strong Catalytic Cooperativity between the Two Nucleotide Sites
Senior, A. E., & Bhagat, S. (1998) · Biochemistry · doi:10.1021/bi9719962 · Cited by 118 · cited 1×
“Two ATP hydrolysis events, which do not occur simultaneously, are needed to transport one drug molecul”
BackgroundMichieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R. J., & Baccarani, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01172.x · Cited by 116 · cited 1×
“PGP expression is correlated with a reduced complete remission rate, and a higher incidence of refractory disease — a surprising finding, as treatment regimens include not only the PGP substrate daunorubicin, but also AraC, which is not a PGP substrat”
BackgroundDetection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen, C. C., Meadows, B., Regis, J. T., Kalafsky, G., Fojo, T., Carrasquillo, J. A., & Bates, S. E. (1997) · PubMed · Cited by 112
Self-citationImmunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Wright, S. R., Boag, A. H., Valdimarsson, G., Hipfner, D. R., Campling, B. G., Cole, S. P. C., & Deeley, R. G. (1998) · PubMed · Cited by 111
Solary, É., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.-Y. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1198.bloodjournal8841198 · Cited by 109
Durand, R. E., & Olive, P. L. (2001) · Methods in cell biology · doi:10.1016/s0091-679x(01)64015-9 · Cited by 107
Vulevic, B., Chen, Z., Boyd, J. T., Davis, W., Walsh, E. S., Belinsky, M. G., & Tew, K. D. (2001) · PubMed · Cited by 107
Peck, R. A., Hewett, J., Harding, M. W., Wang, Y.-M., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H., Atkins, F., & Hawkins, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3130 · Cited by 107
Shen, D., PASTAN, I., & Gottesman, M. M. (1998) · PubMed · Cited by 105
Self-citationExpression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Burger, H., Nooter, K., Gj, Z., Sonneveld, P., van Wingerden, K. E., Oostrum, R. G., & Stoter, G. (1994) · PubMed · Cited by 103
Baekelandt, M. M. O., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000) · PubMed · Cited by 102
Tidefelt, U., Liliemark, J. O., Gruber, A., Liliemark, E., Sundman‐Engberg, B., Juliusson, G., Stenke, L., Elmhorn‐Rosenborg, A., Möllgård, L., Lehman, S., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1837 · Cited by 100
Komatani, H., Kotani, H., Hara, Y., Nakagawa, R., Matsumoto, M., Arakawa, H., & Nishimura, S. (2001) · PubMed · Cited by 98
Shen, D.-W., Goldenberg, S., Pastan, I., & Gottesman, M. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<108::aid-jcp13>3.0.co;2-4 · Cited by 96 · cited 1×
“asp?DrugCode=A%2D3902&DrugName=CISPLATIN+INTRAVEN%2E&DrugType=1">cisplatin”
Self-citationFlasshove, M., Banerjee, D., Mineishi, S., Li, M., Bertino, Jr., & Moore, M. (1995) · Blood · doi:10.1182/blood.v85.2.566.566 · Cited by 96
Sparreboom, A., Planting, A. S., Jewell, R. C., van der Burg, M. E., van der Gaast, A., de Bruijn, P., Loos, W. J., Nooter, K., Chandler, L. H., Paul, E. M., et al. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00005 · Cited by 95 · cited 1×
“The effect varies depending on the anticancer drug used in conjunction with the inhibitor, or even whether the parent drug or a metabolite is administere”
BackgroundMRP and MDR1 gene expression in primary breast carcinomas.
Filipits, M., Suchomel, R. W., Dekan, G., Haider, K., Valdimarsson, G., Depisch, D., & Pirker, R. (1996) · PubMed · Cited by 94
Wilson, W. H., Jamis‐Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Köhler, D., & Wittes, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1985 · Cited by 94
Self-citationMDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Bull, S. B., Aneliunas, V., Lee, P. D., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., Rock, M. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2685 · Cited by 94
Advani, R. H., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001) · PubMed · Cited by 93
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L., Grogan, T. M., & McGuire, W. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2975 · Cited by 92
Starling, J. J., Shepard, R. L., Cao, J., Law, K. L., Norman, B. H., Kroin, J. S., Ehlhardt, W. J., Baughman, T. M., Winter, M. A., Bell, M. G., et al. (1997) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(96)00021-0 · Cited by 91
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
Millward, M., Cantwell, B., Munro, N., Robinson, A., Corris, P., & Harris, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.189 · Cited by 91
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
Chico, I., Kang, M. H., Bergan, R., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R., Choyke, P., Merino, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.832 · Cited by 90
Self-citationKornblau, S. M., Estey, E. H., Madden, T. L., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez‐Williams, G., Kantarjian, H. M., Keating, M. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1796 · Cited by 89
Adhesion-dependent multicellular drug resistance.
Green, S. K., Frankel, A. E., & Kerbel, R. S. (1999) · PubMed · Cited by 89
Lee, E. J., George, S. L., Caligiuri, M. A., Szatrowski, T. P., Powell, B. L., Lemke, S., Dodge, R. K., Smith, R. D., Baer, M. R., & Schiffer, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2831 · Cited by 87
Nooter, K., Bosman, F. T., Burger, H., van Wingerden, K. E., Flens, M. J., Scheper, R. J., Oostrum, R. G., Boersma, A. W. M., van der Gaast, A., & Stoter, G. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010484 · Cited by 84
Laing, N. M., Belinsky, M. G., Kruh, G. D., Bell, D. W., Boyd, J. T., Barone, L. R., Testa, J. R., & Tew, K. D. (1998) · PubMed · Cited by 83
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
Dorr, R., Karanes, C., Spier, C., Grogan, T., Greer, J., Moore, J., Weinberger, B., Schiller, G., Pearce, T., Litchman, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1589 · Cited by 82
Chen, W. S., Luker, K. E., Dahlheimer, J. L., Pica, C. M., Luker, G. D., & Piwnica-Worms, D. R. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00341-5 · Cited by 82
Fracasso, P. M., Westerveldt, P., Fears, C. L., Rosen, D. M., Zuhowski, E. G., Cazenave, L. A., Litchman, M., & Egorin, M. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1124 · Cited by 80
Beketić-Orešković, L., Durán, G. E., Chen, K. G., Dumontet, C., & Sikic, B. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.21.1593 · Cited by 79
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits, M., Suchomel, R. W., Zöchbauer‐Müller, S., Brunner, R., Lechner, K., & Pirker, R. (1997) · PubMed · Cited by 75
Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP)
Hipfner, D., Gao, M., Scheffer, G., Scheper, R., Deeley, R., & Cole, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.642 · Cited by 74
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1173 · Cited by 73
Witherspoon, S. M., Emerson, D. L., Kerr, B. M., Lloyd, T., Dalton, W. S., & Wissel, P. S. (1996) · PubMed · Cited by 67
Robey, R., Bakke, S., Stein, W., Meadows, B., Litman, T., Patil, S., Smith, T., Fojo, T., & Bates, S. (1999) · Blood · doi:10.1182/blood.v93.1.306 · Cited by 64
Self-citationDexter, D., Reddy, R. K., Geles, K. G., Bansal, S., Myint, M. A., Rogakto, A., Leighton, J. C., & Goldstein, L. J. (1998) · PubMed · Cited by 57
Schneider, J., González-Roces, S., Pollán, M., Lucas, R., Tejerina, A., Martín, M., & Alba, A. (2001) · Breast Cancer Research · doi:10.1186/bcr293 · Cited by 53
Multidrug-Resistant Gene Expression in Small-Cell Lung Cancer
Savaraj, N., Wu, C. J., Xu, R., Lampidis, T. J., Lai, S., Donnelly, E., Solomon, J., & Feun, L. G. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199708000-00016 · Cited by 45
Sun, S., Hsieh, J., Tsai, S., Ho, Y., Lee, J.-K., & Kao, C. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00356-6 · Cited by 44 · cited 1×
“Recent imaging studies using 99m Tc (technetium)-sestamibi (Cardiolite), a transport substrate recognized by PGP, indicate that its activity is increased in breast carcinoma”
MethodZhou, Y. F., Gottesman, M. M., & Pastan, I. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1450 · Cited by 42 · cited 1×
“cgi?l=5244">MDR3 (sometimes called MDR2), a phosphatidylcholine FLIPPASE that is closely related to PGP, normally transports phospholipids into bile, but can transport paclitaxel and vinblastine, albeit inefficiently unless it is mutate”
BackgroundSelf-citationKang, M. H., Figg, W. D., Ando, Y., Blagosklonny, M. V., Liewehr, D. J., Fojo, T., & Bates, S. E. (2001) · PubMed · Cited by 39
Self-citationOkawa, T., Kita, M., Arai, T., Iida, K., Dokiya, T., Takegawa, Y., Hirokawa, Y., Yamazaki, K., & Hashimoto, S. (1989) · Cancer · doi:10.1002/1097-0142(19891101)64:9<1769::aid-cncr2820640902>3.0.co;2-g · Cited by 39
Kuttesch, J. F., Parham, D. M., Luo, X., Meyer, W. H., Bowman, L. C., Shapiro, D. N., Pappo, A. S., Crist, W., Beck, W. T., & Houghton, P. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.886 · Cited by 39
Co-expression of the MDR1 gene and HSP27 in human ovarian cancer.
Schneider, J., Jiménez, E., Marenbach, K., Marx, D., & Meden, H. (1998) · PubMed · Cited by 39
Broxterman, H. J., Sonneveld, P., Pieters, R., Lankelma, J., Eekman, C., Loonen, A. H., Schoester, M., Ossenkoppele, G. J., Löwenberg, B., Pinedo, H. M., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401331 · Cited by 39
Expression of Functional Markers in Acute Nonlymphoblastic Leukemia
Han, K., Kahng, J., Kim, M., Lim, J., Kim, Y., Cho, B., Kim, H. K., Min, W. S., Kim, C. C., Lee, K. Y., et al. (2000) · Acta Haematologica · doi:10.1159/000046511 · Cited by 37 · cited 1×
“PGP expression has been reported in leukaemic cells from about one-third of patients with AML at the time of diagnosis, and more than 50% of patients at relapse; higher levels occur in certain subtypes, including secondary leukaemia”
BackgroundKao, C., Tsai, S., Liu, T., Ho, Y., Wang, J., Ho, S., & ChangLai, S.-P. (2001) · PubMed · Cited by 34
Coley, H. M., Verrill, M. W., Gregson, S. E., Odell, D. E., Fisher, C., & Judson, I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00032-0 · Cited by 32 · cited 1×
“Other methodologies, however, have been used to substantiate and refute these findings, and there has been no consensus regarding the effect of PGP on survival in sarcoma”
ResultGorodeski, G. I. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.5.c1495 · Cited by 27
The clinical role of MDR1 gene expression in human lung cancer.
Oka, M., Fukuda, M., Sakamoto, A., Takatani, H., Fukuda, M., Soda, H., & Kohno, S. (1997) · PubMed · Cited by 26
EFFECT OF P-GLYCOPROTEIN EXPRESSION ON OUTCOME IN THE EWING FAMILY OF TUMORS
Perri, T., Fogel, M., Mor, S., Horev, G., Meller, I., Loven, D., Issakov, J., Kollender, Y., Smirnov, A., Zaizov, R., et al. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101300312591 · Cited by 21 · cited 1×
“Other methodologies, however, have been used to substantiate and refute these findings, and there has been no consensus regarding the effect of PGP on survival in sarcoma”
ResultPhase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
Minami, H., Ohtsu, T., Fujii, H., Igarashi, T., Itoh, K., Uchiyama‐Kokubu, N., Aizawa, T., Watanabe, T., Uda, Y., Tanigawara, Y., et al. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01085.x · Cited by 21 · cited 1×
“In the simplest assay, serum can be obtained from patients receiving a PGP inhibitor and assayed for its ability to either reverse multidrug resistance or increase drug accumulation in a PGP-overexpressing cell lin”
Background
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
“MDR occurs because transporter proteins that expel drugs from cells are overexpressed on the surface of cancer cell”
BackgroundPrinciples of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
“Targeting efflux-pump-mediated resistance? A major clinical obstacle that limits the efficacy of cancer therapeutics is the resistance of cancer cells to a multitude of chemotherapeutic and biological agents, known as multidrug resistance (MDR”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.